Ask AI

Search

Updates

Loading...

Table of contents

Bacterial vaginosis

What's new

Updated 2024 WHO guidelines for the treatment of bacterial vaginosis.

Background

Overview

Definition
BV, previously referred to as Gardnerella vaginitis, is a disease resulting from overgrowth of normal vaginal bacterial flora.
1
Pathophysiology
BV is idiopathic; however, sexual transmission has been implicated. It is associated with fluctuations in vaginal microbiota, with a relative increase in Gardnerella vaginalis, Atopobium vaginae, Prevotella species, and Mobiluncus species, in addition, to a decrease in lactobacilli.
1
Epidemiology
In the US, about 7.4 million cases of BV occur yearly. In nonpregnant women with symptomatic vaginal discharge, the overall prevalence of BV is 24.4% based on Nugent's scoring system.
2
Disease course
BV is characterized by milky and malodorous vaginal discharge, resulting in vulvovaginal discomfort and irritation. It has a strong association with preterm birth, first-trimester miscarriage in women undergoing IVF, chorioamnionitis, amniotic-fluid infection, endometritis after childbirth or abortion, and infections after hysterectomy.
2
Prognosis and risk of recurrence
BV has a high recurrence rate of up to 50% within a year of treatment.
1

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of bacterial vaginosis are prepared by our editorial team based on guidelines from the World Health Organization (WHO 2024), the Center for Disease Control (CDC 2021), the American College of Obstetricians and Gynecologists (ACOG 2020), the U.S. Preventive Services Task Force (USPSTF 2020), the International Union Against Sexually Transmitted Infections (IUSTI/WHO ...
Show more

Screening and diagnosis

Indications for screening: as per USPSTF 2020 guidelines, do not obtain screening for BV in pregnant individuals not at increased risk for preterm delivery.
D
Create free account

More topics in this section

  • Diagnostic criteria

Medical management

Antibiotic therapy
As per WHO 2024 guidelines:
Consider offering metronidazole 400 mg or 500 mg PO BID for 7 days in adult and adolescent patients (including pregnant women) with BV.
C
Consider offering the following options if oral metronidazole is not available, adherence to multiple doses is a serious concern, or if vaginal creams are preferred:
metronidazole 0.75% gel intravaginally for 7 days
C
tinidazole 2 g PO as a single dose, except during pregnancy
C
clindamycin 300 mg BID for 7 days
C
clindamycin 2% gel 5 g intravaginally once daily for 7 days
C
secnidazole 2 g PO as a single dose
C

More topics in this section

  • Alternative therapies

  • Management of sexual partners

Specific circumstances

Pregnant patients: as per IUSTI/WHO 2018 guidelines, offer clindamycin for the treatment of BV in pregnant patients.
B

Follow-up and surveillance

Management of recurrent BV: as per IUSTI/WHO 2018 guidelines, offer intravaginal metronidazole in patients with persistent or recurrent BV.
B